Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer Inc (NYSE:PFE) reported first-quarter earnings Wednesday with adjusted EPS of 82 cents. That's down 33% year-over-year, beating the consensus of 54 cents.
輝瑞公司（紐約證券交易所代碼：PFE）週三公佈了第一季度業績，調整後的每股收益爲82美分。同比下降33％，超過了共識的54美分。
The New York-based company witnessed a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%.
這家總部位於紐約的公司目睹了Comirnaty和Paxlovid的全球收入大幅下降，外匯的不利影響爲1.07億美元，跌幅1％。
The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion.
這家美國製藥商公佈的銷售額爲149億美元，下降了20％，超過了共識的142億美元。
- Goldman Sachs maintains the Buy rating with a price target of $31.
- BMO Capital raises the price target from $33 to $36 and reiterates the Outperform rating
- Bank of America Securities maintains a Neutral rating with a price target of $35.
- 高盛維持買入評級，目標股價爲31美元。
- BMO Capital將目標股價從33美元上調至36美元，並重申跑贏大盤的評級
- 美國銀行證券維持中性評級，目標股價爲35美元。
Goldman Sachs: Pfizer shares outperformed after the earnings and interprets the Paxlovid beat without a top-line revenue guidance raise as aligning with the management's tone regarding the 'cautious optimism' near-term outlook.
高盛：輝瑞股價在業績公佈後跑贏大盤，並認爲Paxlovid在沒有提高收入指導的情況下表現與管理層對短期前景的 “謹慎樂觀” 態度一致。
Takeaways include: Padcev impressed, Prevnar did not disappoint, and Vindaqel also delivered.
要點包括：帕切夫給人留下了深刻的印象，Prevnar沒有讓人失望，Vindaqel也表現出色。
In contrast, commercial execution with Nurtec and Oxbryta remains a work in progress. Goldman also highlights Abrysvo (RSV), where upcoming data (2-year) and potential label expansion are fundamental catalysts.
相比之下，Nurtec和Oxbryta的商業執行仍在進行中。高盛還重點介紹了Abrysvo（RSV），其中即將發佈的數據（2年）和潛在的標籤擴張是基本催化劑。
BMO Capital: Pfizer's earnings call was marked by renewed focus (oncology, RSV, hematology). This may finally be the pivot investors have been waiting for, "not because it eliminates challenges, but because it disarms them."
BMO Capital：輝瑞的業績電話會議以新的焦點（腫瘤學、呼吸道合胞病毒和血液學）爲標誌。這可能最終是投資者一直在等待的支點，“不是因爲它消除了挑戰，而是因爲它使他們擺脫了武裝。”
BMO expects margin improvement, giving guidance that reflects well-managed expectations with room for upside on the top and bottom lines.
BMO預計利潤率將提高，給出的指導方針反映了管理良好的預期，收入和利潤都有上行空間。
BofA Securities: The firm remains focused on Pfizer's six new product launches (Nurtec/Vydura, Oxbryta, Abrysvo, Elrexfio, Velsipity, and Litfulo) and two label expansions (Padcev in 1L bladder cancer and Xtandi in nmCSPC with higher-risk BCR).
美銀證券：該公司仍然專注於輝瑞的六款新產品的推出（Nurtec/Vydura、Oxbryta、Abrysvo、Elrexfio、Velsipity和Litfulo）和兩項標籤擴張（Padcev用於1L膀胱癌，NMCSPC的Xtandi風險較高的BCR）。
Currently, there's evident growth stemming from the label expansions with Padcev, the BofA analyst writes.
美國銀行分析師寫道，目前，Padcev的標籤擴張帶來了明顯的增長。
According to first-quarter discussions, it's uncertain when other important products will experience a significant change in 2024. That's mainly due to challenges related to reimbursement and access.
根據第一季度的討論，尚不確定其他重要產品何時會在2024年發生重大變化。這主要是由於與報銷和准入相關的挑戰。
Price Action: PFE shares are up 2.15% at $27.77 at last check Thursday.
價格走勢：週四最後一次檢查時，PFE股價上漲2.15％，至27.77美元。
Now Read: Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
立即閱讀：輝瑞預計來自Covid-19治療的收入減少，股票在第一季度業績前面臨阻力